(Q38229304)

English

Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts

scientific article published on July 2014

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

author name string

Paul L McCormack

1

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

publication date

1 July 2014

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

74

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

1253-1283

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

The global health burden of infection-associated cancers in the year 2002

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Human papillomavirus vaccines: current status and future prospects

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Evaluation of the HPV 18 antibody response in Gardasil® vaccinees after 48 mo using a pseudovirion neutralization assay

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Near elimination of genital warts in Australia predicted with extension of human papillomavirus vaccination to males.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany-an ecologic study

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

HPV vaccine against anal HPV infection and anal intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Anaphylaxis following quadrivalent human papillomavirus vaccination

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Safety of quadrivalent human papillomavirus vaccine administered routinely to females

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Detection of human papillomavirus (HPV) L1 gene DNA possibly bound to particulate aluminum adjuvant in the HPV vaccine Gardasil

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Adverse events following immunization in Ontario's female school-based HPV program

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Human papillomavirus vaccine in boys: background rates of potential adverse events

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Cost-effectiveness of human papillomavirus vaccination in the United States

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Health and economic implications of HPV vaccination in the United States

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases: the BEST study

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

The cost-effectiveness of male HPV vaccination in the United States

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Impact of vaccinating boys and men against HPV in the United States

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Model for assessing human papillomavirus vaccination strategies

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Economic evaluation of human papillomavirus vaccination in the United Kingdom

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Evaluating human papillomavirus vaccination programs

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Modeling preventative strategies against human papillomavirus-related disease in developed countries

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Acceptance of the HPV vaccine among women, parents, community leaders, and healthcare providers in Ohio Appalachia

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Predictors of parents' willingness to vaccinate for human papillomavirus and physicians' intentions to recommend the vaccine

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

High uptake of Gardasil vaccine among 9 - 12-year-old schoolgirls participating in an HPV vaccination demonstration project in KwaZulu-Natal, South Africa

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Achieving high coverage in Rwanda's national human papillomavirus vaccination programme

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Assessment of eight HPV vaccination programs implemented in lowest income countries

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Too fast or not too fast: the FDA's approval of Merck's HPV vaccine Gardasil

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0255-Z

21 January 2018

Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 –- conclusions and recommendations

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development and duration of human papillomavirus lesions, after initial infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systematic review of human papillomavirus vaccine coadministration

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

National and state vaccination coverage among adolescents aged 13-17 years--United States, 2012.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human papillomavirus vaccine safety in pediatric patients: an evaluation of the Vaccine Adverse Event Reporting System

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High incidence of cervical human papillomavirus infection in women during their first sexual relationship

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HPV vaccine works against nine viral types

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, tolerability, and immunogenicity of gardasil given concomitantly with Menactra and Adacel

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human papilloma virus vaccination in Nepal: an initial experience in Nepal.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Health and economic impact associated with a quadrivalent HPV vaccine in Italy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence of genital warts among U.S. service members before and after the introduction of the quadrivalent human papillomavirus vaccine.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in health

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chapter 2: The burden of HPV-related cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Post-vaccination anti-human papillomavirus antibody seroprevalence among Czech teenaged girls and women

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human papillomavirus vaccines. WHO position paper

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25022951

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40265-014-0255-Z

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38229304&oldid=2201439668"